Although ␥-aminobutyric acid (GABA) A receptor ␣ subunits are important for benzodiazepine (BZD) binding and GABA-current potentiation by BZDs, the presence of a ␥ subunit is required for high affinity BZD effects. To determine which regions unique to the ␥2S subunit confer BZD binding and potentiation, we generated chimeric protein combinations of rat ␥2S and ␣1 subunits using a modified protocol to target crossover events to the amino-terminal extracellular region of the subunits. GABA A receptors are the major inhibitory neurotransmitter receptors in the mammalian brain and are members of a ligand-gated ion channel superfamily (Ortells and Lunt, 1995) , which includes receptors for acetylcholine, glycine, and serotonin. Molecular cloning studies have identified several different classes and isoforms of GABA A receptor subunits, including 6 ␣, 4 ␤, 3 ␥,1 ␦, and 2 subunit subtypes (Sieghart, 1995) . The majority of the GABA A receptors in the brain are likely to consist of ␣1, ␤2, and ␥2 subunits (Stephenson, 1995) . These receptors are pentameric proteins containing an integral chloride-selective channel with specific binding sites for GABA, BZDs, barbiturates, steroids, and picrotoxin (Sieghart, 1995; Smith and Olsen, 1995) . BZDs, clinically used for their anxiolytic, muscle-relaxant, sedative, and antiepileptic actions, exert their therapeutic effects by allosterically modulating the activation of the GABA A receptor. Because of their clinical usefulness, a substantial effort has been made to understand the structural determinants within the receptor that underlie BZD binding and allosteric coupling.
GABA A receptors are the major inhibitory neurotransmitter receptors in the mammalian brain and are members of a ligand-gated ion channel superfamily (Ortells and Lunt, 1995) , which includes receptors for acetylcholine, glycine, and serotonin. Molecular cloning studies have identified several different classes and isoforms of GABA A receptor subunits, including 6 ␣, 4 ␤, 3 ␥,1 ␦, and 2 subunit subtypes (Sieghart, 1995) . The majority of the GABA A receptors in the brain are likely to consist of ␣1, ␤2, and ␥2 subunits (Stephenson, 1995) . These receptors are pentameric proteins containing an integral chloride-selective channel with specific binding sites for GABA, BZDs, barbiturates, steroids, and picrotoxin (Sieghart, 1995; Smith and Olsen, 1995) . BZDs, clinically used for their anxiolytic, muscle-relaxant, sedative, and antiepileptic actions, exert their therapeutic effects by allosterically modulating the activation of the GABA A receptor. Because of their clinical usefulness, a substantial effort has been made to understand the structural determinants within the receptor that underlie BZD binding and allosteric coupling.
Evidence suggests that both the ␣ and ␥ subunits play critical roles in BZD binding and potentiation. By analogy to the agonist binding site of the nicotinic acetylcholine receptor (Karlin and Akabas, 1995) , the BZD binding site of the GABA A receptor has been modeled with a ␥ subunit apposed to an ␣ subunit, with adjacent faces of the subunits contributing to the binding site (Smith and Olsen, 1995) . Alternatively, any subunit may bind BZD itself but have this ability enhanced by conformational changes conferred by the presence of the ␥ subunit, which is required for high affinity BZD effects (Pritchett et al., 1989) . Regardless, understanding the roles of the ␣ and ␥ subunits in BZD binding and modulation requires discovery of the specific structural elements involved.
In the ␣1 subunit, several amino acid residues have been identified that are important for BZD effects. Photoaffinitylabeling (Smith and Olsen, 1995; Duncalfe et al., 1996) and mutagenesis experiments (Wieland et al., 1992; Kleingoor et al., 1993) have identified histidine at position 101 (H101) as (Boileau et al., 1996). forming part of the BZD binding site. Experiments using ␣1/␣3 chimeras point to ␣1G200 as another potential site for BZD effects (Pritchett and Seeburg, 1991) . Other residues in ␣1 implicated in BZD binding include T162 and V211 (Wieland and Luddens, 1994) , Y161 and T206 (Buhr et al., 1996) , and Y159 and Y209 (Amin et al., 1997) . Taken together, these results suggest that three separate domains of the ␣1 subunit, near H101, Y159-T162, and G200-V211, are involved in BZD binding.
Less evidence has been gathered regarding the BZD-responsive regions of the ␥ subunit. Mutagenesis experiments have identified two amino acids (F77 and T142) in the ␥2 subunit that may play a role in BZD effects. Mutation of Thr142 to serine (␥2T142S) altered the efficacy of several BZD ligands; both an antagonist (Ro15-1788) and a weak inverse agonist (Ro15-4513) took on the character of partial agonists (Mihic et al., 1994) . Mutation of Phe77 to leucine (␥2F77L) enhanced diazepam potentiation of the GABA-mediated Cl Ϫ current (Buhr et al., 1996) , even though the binding affinity of diazepam was reduced. Substitution of ␥2F77 with other amino acids had complex effects on BZD pharmacology .
Both ␥2F77 and ␥2T142 are conserved in the aligned sequence of ␣1. The ␣ subunit, even though it contains the homologous phenylalanine and threonine residues, cannot substitute for a ␥ subunit in conferring BZD effects. ␣␤ receptors do not bind BZDs or exhibit BZD-induced potentiation of the GABA-activated Cl Ϫ current, whereas ␣␤␥ receptors do. Thus, other residues specific to the ␥ subunit are required for BZD binding and modulation.
To determine which regions unique to the ␥2S subunit confer BZD binding and potentiation, we generated chimeric protein combinations of rat ␥2S and ␣1 subunits. Chimeric studies have the potential to target whole domains, which is important if we envision the drug binding site as a pocket formed by the side chains of a variety of amino acids from one or more regions of a subunit. Using this method, we identified two domains of ␥2S that are, in conjunction, necessary and sufficient for high affinity BZD binding. In addition, we demonstrated that the ␥2S regions responsible for high affinity BZD binding are distinct from the ␥2S regions necessary for efficient allosteric coupling of the BZD binding site to the GABA binding site. The construction of chimeric subunits that exhibit wild-type binding but reduced allosteric coupling of GABA and BZD binding sites affords new probes for elucidating the structural components of allosteric modulation.
Materials and Methods
Molecular cloning. Chimeras () were generated by placing the rat ␥2 coding region 5Ј to and in register with the rat ␣1 sequence in pBlueScript SK Ϫ (Stratagene, La Jolla, CA). The dual plasmid (pTRCP, Fig. 1A ) was digested, and the linearized plasmid was recircularized in bacteria by random homologous crossover events (Moore and Blakely, 1994) . To create chimeric subunits containing amino-terminal domains of the ␥2S subunit and carboxyl-terminal domains of the ␣1 subunit, we cut the dual-subunit plasmid with a restriction enzyme that cuts only in each coding region of ␥2S and ␣1 (either AflII or BbsI). A fragment consisting mostly of the transmembrane and 3Ј coding regions of ␥2S was released. The remaining linearized plasmid contained ␥2S and ␣1 sequences with restricted regions of homology. Because appropriate crossovers can occur only in a small area delimited by the chosen restriction enzyme or enzymes, we named this method TRCP. Using this method, dozens of chimeric subunits with crossovers in the 5Ј (extracellular) region were generated in XL1-Blue cells, an endA Ϫ strain that facilitates plasmid miniprep production. The chimeric open reading frames were subcloned into pGH19 (Liman et al., 1992; Robertson et al., Fig. 1 . TRCP. A, Chimeras were generated by placing the ␥2S coding region (2.0 kb) 5Ј to and in register with the ␣1 sequence (1.65 kb) in pBlueScript SK Ϫ (2.9 kb; Stratagene) to yield pTRCP (6.55 kb). When linearized and introduced into competent coliform cells, the plasmid was recircularized by crossover events in homologous regions within the plasmid construct (see Materials and Methods). By choosing restriction enzymes that cut both ␥2S and ␣1 (e.g., AflII), the transmembrane and 3Ј coding region of ␥2 was released, and sufficient ␣1 and ␥2 5Ј sequence was left to allow for crossover events. Black, ␥2S sequence. White, ␣1 sequence. Gray, crossover areas made available by digestion with AflII. B, TRCP chimeras were screened from four independent trials and contained 5Ј ␥2S and 3Ј ␣1 sequence, the amount of which was determined by restriction digest mapping and DNA sequencing. The chimeras () generated by TRCP are named for the amino acid of where the crossover transitions occurs and fell into six major groups (40, 82, 107, 113, 161, and 167) . Three additional non-TRCP chimeras were made (see Materials and Methods) and are named for the ␥2S segments each contains. For example, 40/114 -161 contains ␥2S sequence from Q1 to N40 and from R114 to D161. 114 -161 contains only ␥2S sequence from R114 to D161. Black, ␥2S sequence. White, ␣1 sequence. Gray, transmembrane segments M1 through M4. 1996) for expression in oocytes or into pCEP4 (InVitrogen, San Diego, CA) for transient expression in HEK 293 cells. For the TRCP chimeras generated in this study (Fig. 1B) , the ␥2S and ␣1 amino acids at which the crossovers occur are ␥N40/␣R28 (40), ␥W82/␣K70 (82), ␥W107/␣T95 (107), ␥F113/␣H101 (113), ␥D161/␣A149 (161), and ␥L167/␣K155 (167). Chimeras 40, 82, 107, and 113 were generated by AflII digestion, whereas 161 and 167 used BbsI digestion.
Chimera 114-161 (Fig. 1B) was produced by recombinant polymerase chain reaction using an oligonucleotide (5Ј-CCAGTA-AAATCTGGACTCCAGACACTTTCTTCAGGAACTCC-3Ј) designed to create an ␣F100/␥R114 crossover. Using this 5Ј oligonucleotide and a downstream complementary ␣1 oligonucleotide (5Ј-CTGG-GAGAGAATGACTGTC-3Ј) with chimera 161 as template, a 456-base pair polymerase chain reaction fragment with ␣1 5Ј and 3Ј flanks and ␥2 114-161 sequence was generated and subcloned into wild-type ␣1 cDNA using BalI and NsiI. The resulting chimera contained ␣1 sequence except in the region from H101 to D148. This region contained the homologous ␥2 region (R114 to D161). Chimeras 40/114-161 and 82/114-161 (Fig. 1B) were produced by digesting 114-161 with MscI and NdeI, which flank the ␥2 114-161 sequence, and subcloning the resultant 749-base pair fragment into 40 and 82. The resulting chimeras replaced the ␣1 region from H101 to D148 in both 40 and 82 with the homologous ␥2S region (R114-D161). All chimeras were verified by restriction digest and doublestranded DNA sequencing using standard techniques (Sambrook et al., 1989) .
Transient expression in HEK 293 cells. Rat ␣1, ␤2, ␥2S, and chimeric subunit cDNAs were subcloned into the multiple cloning site of a mammalian expression vector (pCEP4; InVitrogen) for transient transfection of HEK 293 cells (American Type Culture Collection CRL 1573). Cells were grown onto 100-mm tissue culture dishes in minimum essential medium with Earle's salts (Life Technologies, Grand Island, NY) containing 10% fetal bovine serum (Hyclone Laboratories, New Brunswick, NJ) in a 37°incubator under a 5% CO 2 atmosphere. Cells were cotransfected at 40-50% confluency with pCEP-␣1, pCEP-␤2, pCEP-␥2, and/or pCEP-using a standard CaHPO4 method (Graham and Eb, 1973) . In general, cells were transfected with equal ratios of subunit DNA (5 g/subunit). Cells were harvested and membrane homogenates prepared 48-72 hr after transfection.
Binding assays. Cells were scraped from the dishes and pelleted by centrifugation (1000 ϫ g, 10 min, 4°). The cells were washed once and resuspended in a HEPES buffer containing 124 mM NaCl, 2.9 mM KCl, 1.3 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 25.0 mM HEPES, 5.2 mM D-glucose, and 2 mM EDTA; pH 7.4 and homogenized using a Polytron homogenizer (Brinkmann Instruments, Westbury, NY). The homogenates were centrifuged (30,000 ϫ g, 20 min, 4°), and the resulting pellets were resuspended in HEPES buffer. Protein concentrations were determined using a Bradford assay (BioRad, Hercules, CA) with bovine serum albumin as a standard.
For BZD saturation binding experiments, membrane homogenates (100 g) were incubated at room temperature with seven to nine concentrations of [ 3 H]Muscimol (15.7 Ci/mmol; DuPont-New England Nuclear) binding experiments were performed similarly; 1 mM GABA or 100 M muscimol was used to determine nonspecific binding. All points were determined in triplicate. After reaching equilibrium, the incubations were vacuum filtered through glass-fiber filters (Reeves Angels; Whatman, Clifton, NJ) using a cell harvester (model MB-48; Brandel, Montreal, Quebec, Canada) and washed with eight times with 0.25 ml of HEPES buffer. Specific binding was defined as the amount of tritium bound in the absence of displacing ligand minus the amount bound in the presence of displacer. Nonspecific binding was ϳ20-30% of total binding at K D concentrations of radioligand. In general, K D and B max were determined by fitting specific binding data to a single site using the equation y ϭ B max *x/(K D ϩ x), where y is specifically bound dpm, and x is the radiolabeled drug concentration (Prism; GraphPAD Softward, San Diego, CA).
Competition experiments with various BZD-site ligands were done under the same general conditions, except seven to nine concentrations of nonradioactive competing ligand were used to displace specifically bound radioligand. Data were fit by using a nonlinear leastsquares method to the equation y ϭ B max /[1ϩ (x/IC 50 )], where y is the specifically bound dpm, B max is maximal binding, and x is the concentration of displacing drug (Prism). K I was calculated according to the Cheng-Prusoff/Chou equation (Cheng and Prusoff, 1973; Chou, 1974) .
To measure GABA potentiation of [ 3 H]flunitrazepam binding (Czajkowski et al., 1989) , membrane homogenates were incubated for 60 min at room temperature with 3-5 nM [
3 H]flunitrazepam in the presence of six different concentrations of GABA (ranging from 100 nM to 10 M) and then filtered as described. The potentiation was calculated for each GABA concentration as follows: p ϭ (dpm GABA / dpm control ) Ϫ 1, where dpm GABA is the specific [
3 H]flunitrazepam bound in the presence of GABA, and dpm control is the specific [ 
Expression in oocytes.
Capped cRNA coding for the wild-type and chimeric subunits was synthesized by in vitro transcription from NheI-linearized cDNA template using the mMessage mMachine T7 kit (Ambion, Austin, TX). Oocytes from Xenopus laevis were prepared by incubating small pieces of ovary in collagenase (2 mg/ml) in ND96/Ca 2ϩ -free media containing 96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , and 5 mM HEPES, pH 7.6, for 40 min at room temperature. The digested ovaries were washed several times in ND96, followed by several washes in recording solution (ND96 with 1.8 mM CaCl 2 ). Individual oocytes were defolliculated manually or en masse by 40-min incubation at room temperature in osmotic shock solution (130 mM K 2 HPO 4 , 1 mg/ml bovine serum albumin, pH 6.5 with HCl; Pajor, 1995) followed by several washes in recording solution. Within 1 day, they were injected with 5-50 nl of mRNA (10-200 pg/nl/subunit) mixed in a ratio of 1:1 (␣:␤, ␤:␥, or ␤:) or 1:1:10 (␣:␤:␥ or ␣:␤:). These ratios were determined to produce maximal assembly of ␥-or -containing channels (Boileau AJ and Czajkowski C. Improved measurements of GABA-elicited currents and diazepam potentiation in recombinant GABA A receptor channels expressed in Xenopus oocytes, manuscript in preparation). Oocytes were stored at 17-19°in recording solution supplemented with 100 g/ml gentamicin and 100 g/ml bovine serum albumin and were used for electrophysiological experiments 2-14 days after injection. The total amount of cRNA was scaled to yield maximal GABA-induced currents of ϳ3-8 A for ␣1␤2␥2S and ␣1␤2. The ␤2␥2S and ␤2 subunit combinations yielded less current, usually 0.5-3 A. cRNA concentrations were calculated by UV absorption and corroborated by comparison with RNA standards on 1.5% agarose gels.
Voltage-clamp analysis. Oocytes under two-electrode voltageclamp (V hold ϭ Ϫ80 mV) were perfused continuously with ND96/ Ca 2ϩ recording solution at a rate of 5 ml/min. In general, drugs and reagents were dissolved in ND96/Ca 2ϩ . The stock diazepam solution was made in dimethylsulfoxide. No differences in currents were observed with the vehicle. GABA responses were scaled for run-down or run-up by comparison with a low, nondesensitizing concentration of drug applied just before the drug concentration tested. Diazepam potentiation was recorded at ϳEC 7 to EC 20 for GABA (1 M GABA for ␣1␤2␥2S and ␣1␤2, 40 M GABA for ␤2␥2S). Data acquisition and analysis were performed using AxoData, AxoGraph (Axon Instruments), and Prism (GraphPAD Software, San Diego, CA). All statistical comparisons used Student's t test for independent samples (Snedecor and Cochran, 1980) .
Results

BZD and GABA Binding to ␣␤ Receptors
To create chimeric subunits containing amino-terminal domains of the ␥2S subunit and carboxyl-terminal domains of the ␣1 subunit, we modified a published method (Moore and Blakely, 1994) to specifically target crossovers to occur in the extracellular amino-terminal domain before M1 (see Materials and Methods; Fig. 1A ). Chimeras () used here, named for the ␥2S amino acid at which the crossovers occur, are 40, 82, 107, 113, 161, and 167 (Fig. 1B) .
To determine whether the chimeric subunits contained appropriate ␥2S domains for BZD binding, they were individually expressed with wild-type ␣1 and ␤2 subunits in HEK 293 cells to form ␣1␤2 receptors, and the binding of 100 nM 3 H]muscimol binding measured are 2-5-fold lower than values reported by others in the field due to different assay conditions. In our binding assays, incubations with radioligand are carried out at room temperature (as opposed to on ice or 4°) to more closely mimic our electrophysiological recording conditions. Table 1. the GABA response when coexpressed with wild-type ␣1 and ␤2 cRNA in X. laevis oocytes, whereas 161 and 167 exhibited small but detectable amounts of potentiation. The traces in Fig. 4A show diazepam potentiation of GABA-activated currents from oocytes expressing ␣1␤2␥2S, ␣1␤2161, and ␣1␤2167 GABA A receptors. Fig. 4B plots the potentiation of GABA-activated currents for ␣1␤2␥2S, ␣1␤2161, ␣1␤2167, and ␣1␤2 receptors as a function of diazepam concentration. The maximal diazepam potentiation of ␣1␤2161 and ␣1␤2167 receptors was dramatically lower (ϳ7-fold) than that for wild-type ␣1␤2␥2S receptors (Table 2 ). This result was surprising, considering that ␣1␤2161 and ␣1␤2167 receptors bound BZDs with wild-type affinity (Table 1) , and indicates an uncoupling of high affinity BZD binding from BZD potentiation. Although the potentiation of ␣1␤2161 and ␣1␤2167 receptors was small, it was significant ( p Ͻ 0.05) at diazepam concentrations above 100 nM compared with ␣1␤2, ␣1␤240, or ␣1␤2113 (Table 2) . On normalization of the data to maximal potentiation, a ϳ6-fold increase in the EC 50 for diazepam potentiation was observed in 161-and 167-containing receptors compared with wild-type receptors ( Fig. 4B, inset ; Table 2 ).
Because a change in GABA EC 50 value could potentially explain the decrease in BZD potentiation observed, GABA dose responses were measured. Current amplitudes at 1 M (test concentration) and 10 mM GABA (maximal concentration) for all six ␣1␤2 combinations (data not shown) and GABA dose-response curves for ␣1␤2161 and ␣1␤2167 were similar to those for wild-type ␣1␤2␥2S receptors (Fig. 5 , Table 2 ). These data indicate that the decrease in diazepam potentiation measured for ␣1␤2161 and ␣1␤2167 receptors was not caused by an alteration in GABA-mediated activation. Interestingly, the GABA EC 50 values for ␣1␤2␥2S, ␣1␤2161, and ␣1␤2167 receptors were statistically different than that for ␣1␤2 receptors ( p Ͻ 0.001, Table 2 ). The small change in GABA potency in the triple subunit combinations compared with ␣1␤2 receptors may be indicative of the presence of the ␥2S subunit or domains (see Discussion) and suggests that after injection of ␣1␤2 subunit combinations into X. laevis oocytes, a majority of the expressed receptors contain a chimeric subunit.
Equilibrium binding studies. To gain further insight into whether the decrease in the allosteric coupling of the GABA and BZD binding sites was due to an intrinsic property of the chimera-containing receptors, the ability of GABA to potentiate [ 3 H]flunitrazepam binding to membrane homogenates prepared from HEK 293 cells expressing ␣1␤2␥2S, ␣1␤2161, and ␣1␤2167 receptors was measured. In this experimental paradigm, only the receptor populations containing a ␥2S or chimeric subunit were monitored because ␣1␤2 receptors do not bind BZDs. Fig. 6 plots the potentiation of specific [ (1:1:10), ␣1␤2 (1:1), and ␣1␤2 (1:1:10) cRNA mixtures were treated with a range of diazepam concentrations in the presence of GABA and further analyzed. A potentiation response ratio was determined by dividing the peak current for ␣1␤2␥2S (f), ␣1␤2 (F), ␣1␤2161 (Ⅺ), and ␣1␤2167 (E) exposed to 1 M GABA plus diazepam (DZ) by the response to 1 M GABA alone. Data were fitted to a curve described by the equation
where Max is the maximal potentiation, Min is the potentiation at the lowest drug concentration tested, X is the logarithm of diazepam concentration, EC 50 is the halfmaximal potentiation response, and n is the Hill coefficient. Data points represent mean potentiation from four or more cells from two or more batches of oocytes. Error bars, standard deviation. The parameters from the curve fits are presented in Table 2 . Inset, a plot of the same data after normalizing to the maximum response for ␣1␤2␥2 (f), ␣1␤2161 (Ⅺ), and ␣1␤2167 (E) receptors displays the shift in EC 50 value for chimeracontaining receptors. (Fig. 6) . These results suggest that the BZD and GABA binding sites are uncoupled in ␣1␤2161 and ␣1␤2167 receptors and that the uncoupling is due to a property of the chimera-containing receptors. In addition, these results corroborate the markedly reduced diazepam potentiation observed electrophysiologically.
Benzodiazepine Binding and Allosteric Coupling of ␥-Aminobutyric
Further Localization of the BZD Binding Site
By comparing the ␥/␣ crossover positions (Fig. 1B) in chimeras that bound BZDs with high affinity (161, 167) with those that did not (40, 82, 107 , and 113), a region of 48 amino acid residues (R114-D161) of the ␥2S subunit that is essential for BZD binding can be identified. This determination requires that ␣1␤2 receptor combinations using 40, 82, 107, or 113 subunits were assembled and expressed efficiently. To address this question, the chimeric subunits were individually expressed with ␤2 subunits in X. laevis oocytes and the ability of GABA to activate a Cl Ϫ -specific current was tested. Because the dual subunit combinations ␣1␤2 and ␤2␥2S form functional GABA-gated receptors when expressed in X. laevis oocytes (Table 2; Sigel et al., 1990) and ␤2 subunits expressed alone cannot, expression of ␤2 combinations directly tests the capability of the chimeras to assemble into functional receptors. We observed GABA-mediated Cl Ϫ currents using all six ␤2 subunit combinations (data not shown). ␤240, ␤282, ␤2161, and ␤2167 had maximal GABA current amplitudes similar to ␤2␥2S (3Ն A). The maximal GABA currents of ␤2107 and ␤2113 receptors were ϳ5-fold smaller. Interestingly, although diazepam potentiated the GABA response in ␤2␥2S receptors (EC 50 ϭ 24 Ϯ 2 nM), diazepam did not potentiate the GABA current of any of the ␤2 receptors (see Discussion). Nevertheless, these results demonstrate that the chimeric subunits can be assembled into functional ␤2 receptors. If the chimeric subunits assemble into functional ␣1␤2 receptors in a similar manner, a region of 48 amino acids delimited by 113 to 161 in ␥2S is required for BZD binding.
To determine whether this region is not only necessary but also sufficient for BZD binding, a chimeric subunit (114 -161, Fig. 1B ) was constructed that replaced the region from H101 to D148 in the ␣1 subunit with the homologous ␥2S region (R114-D161). This chimera, when expressed with wild-type ␣1 and ␤2 subunits, did not specifically bind 5 . GABA dose response for chimeras is similar to that of wild-type ␣1␤2␥2 receptors. Oocytes were injected with ␣1␤2␥2 (1:1:10, f), ␣1␤2
(1:1, F), ␤2␥2 (1:1, OE), and ␣1␤2161 (1:1:10, Ⅺ) cRNA to determine whether reduced diazepam potentiation of chimeras was due to any shift in GABA dose-response curves. Data were fitted to a curve described by the equation
}, where Max is the maximal response, Min is the response at the lowest drug concentration tested, X is the logarithm of GABA concentration, EC 50 is the half-maximal response, and n is the Hill coefficient. Dose response for both ␣1␤2161 and ␣1␤2167 (not shown, for clarity) are most similar to that of wild-type ␣1␤2␥2. Data points, mean peak current from four or more cells from two or more batches of oocytes; error bars, standard deviation. Parameters determined from the curve fits are presented in Table 2 . 3 H]flunitrazepam binding was measured in membrane homogenates prepared from HEK 293 cells expressing ␣1␤2␥2 (f) and ␣1␤2161 (Ⅺ) receptors (see Materials and Methods). Potentiation was calculated by dividing specific dpm in the presence of GABA by specific dpm in the absence of GABA, and the resulting data were fit to a single-site sigmoidal dose-response curve (see Materials and Methods; Fig. 4 These data suggest that the lack of BZD binding by ␣1␤2114 -161 receptors cannot be explained by an impairment in the assembly or expression of the 114 -161 subunit. Therefore, although the R114-D161 region of ␥2S may be necessary for BZD binding, it clearly is not sufficient.
Because 114 -161 did not bind BZDs, two ␥/␣/␥/␣ chimeras were constructed (40/114 -161 and 82/114 -161; Fig.  1B ) that replaced in both 40 and 82 the ␣1 region from H101 to D148 with the homologous ␥2S region (R114-D161). These chimeras were expressed with wild-type ␣1 and ␤2 subunits in HEK 293 cells and the binding of (Fig. 7) . ␣1␤282/114 -161 receptors showed no significant differences from ␣1␤2␥2S receptors in the K I values for Ro15-1788 (K I ϭ 12.7 Ϯ 3.1 nM, three experiments) or Ro15-4513 (K I ϭ 23.0 Ϯ 9.4 nM, four experiments). Thus, only two regions of the ␥2S subunit, Q1-W82 and R114-D161, are required for high affinity BZD binding. Amino acid sequence comparison of ␣1␤240/114 -161 receptors, which do not bind BZDs, and ␣1␤282/114 -161 receptors suggests that high affinity BZD binding requires only the ␥2S domains K41-W82 and R114-D161.
Discussion
TRCP. The use of TRCP was successful. By choosing available restriction sites, we specifically targeted DNA sequence crossovers to the amino-terminal regions of the ␣1 and ␥2S subunits (see Materials and Methods). Moreover, by engineering a sequence with silent mutations to provide new restriction enzyme sites, one could choose any region to target for crossover events. Thus, TRCP should prove useful for any multisubunit protein.
Despite relatively low amino acid identity , the intersubunit chimeras described in this study (␥2S/␣1) formed functional channels. Intersubunit chimeras can furnish different structural/functional information from that furnished by subunit subtype chimeras (e.g., ␣1/␣3), such as determining areas that are unique to each subunit and regions that are interchangeable between subunits. This was particularly useful because we were interested in identifying structural determinants of BZD binding and potentiation that were unique to the ␥ subunit.
Identification of ␥2S BZD binding region. The results demonstrate that a chimeric subunit with ␥2S sequence in the first 161 amino acid residues and ␣1 sequence in the remainder can efficiently substitute for a wild-type ␥2S subunit in assembling functional cell surface GABA A receptors that bind BZDs with high affinity. This proves that the ␥2S determinants for binding BZD agonists (diazepam and flunitrazepam), inverse agonists (Ro15-4513), and antagonists (Ro15-1788) lie in the major extracellular portion of the subunit from the amino terminus through the cysteine-cysteine loop. Because electrophysiological experiments with ␤2 combinations indicate that all of the chimeric subunits are expressible, we assume the chimeras also are expressed in ␣1␤2 receptors. Amino acid sequence comparison of ␣1␤2113 receptors, which do not exhibit BZD binding, with ␣1␤2161 receptors leads to the conclusion that high affinity BZD binding requires ␥2S domain or domains between amino acid residues 113 and 161. However, a chimera that contains only these ␥2S residues (the ␣/␥/␣ chimera, 114-161), does not exhibit BZD binding, demonstrating that this 48-amino acid span is not sufficient for high affinity BZD binding. In other words, elements of ␥2S upstream from position 114 must be involved in the formation of the binding pocket.
A chimera that contains the amino-terminal 82 amino acid residues from ␥2S in addition to residues 114-161 (the ␥/␣/ ␥/␣ chimera, 82/114-161) bound BZDs when expressed with ␣1 and ␤2 subunits. This result demonstrates that the ␥2 subunit determinants for expression of high affinity BZD binding are contained within two domains of the ␥2 subunit, Q1-W82 and R114-D161. Furthermore, if 40/114-161, which does not bind BZDs, is expressed, the results indicate that BZD binding requires the ␥2S domains K41-W82 and R114-D161. Although direct evidence that 40/114-161 is expressed is not shown, it is reasonable to assume that it is because both 40 and 114-161 are expressed.
It has been postulated that the BZD and GABA binding sites are conserved structures, with a BZD binding site at a ␥/␣ subunit interface and a GABA binding site at an ␣/␤ interface. Many of the ␥/␣ interface residues that have been identified as being important for BZD binding (␥2F77, ␣1Y159, ␣1T206, and ␣1Y209) are homologous to the ␣/␤ interface residues that are important for binding GABA (␣1F64, ␤2Y157, ␤2T202, and ␤2Y205). In the aligned sequences of the subunits, these residues are conserved. However, because the molecular structures of GABA and BZDs are quite distinct, it seems likely that other nonconserved residues will be required to impart pharmacological specificity to these sites.
Our results confirm the potential roles for ␥2F77 and/or ␥2T142 in BZD effects. These residues, which have previously been implicated in BZD effects (Mihic et al., 1994; Buhr et al., 1996 , occur within the two ␥2 regions identified in this study. However, although these residues may be important for BZD binding, both are conserved between the ␣1 and ␥2 subunits. Thus, other ␥2 residues are needed to impart a unique ␥2 flavor and pharmacologically distinguish the BZD binding site pocket from the GABA binding site pocket. In this study, we have localized the specific ␥2 determinants for BZD binding to K41-W82 and R114-D161. A recent study using ␥3/␥2 chimeras has identified one amino acid residue (␥2 M130) and perhaps a second (␥2 M57) that seem to be important for controlling the affinity of zolpidem, an imidazopyridine. These residues occur within the two ␥2 regions identified in this study. Mutations of these residues, however, have little or no effect on binding of classic BZDs. Thus, although subunit subtype chimeras are useful in examining the subtle pharmacological differences between ␥ subunits, these types of chimeras are not as helpful for identifying residues that are absolutely necessary for BZD binding. In our study, the novel use of ␥2/␣1 intersubunit chimeras allowed us to identify two distinct regions unique to the ␥ subunit that are required for the high affinity binding of a variety of different types of BZD ligands. Galzi and Changeux (1994) proposed a four-loop model for ligand binding. Perhaps the three potential BZD binding regions of ␣1 (H101, Y159-T162, and G200-V211) correspond to three of these loops. If the model holds true, our results suggest that the fourth loop, presumed to be a part of an adjacent subunit, is contributed by residues in two regions of the ␥2 subunit (K41-W82 and R114-D161). Moreover, if the GABA-binding region of ␣ is homologous to the BZD-binding region of ␥, then our finding that more than one region in the ␥ subunit is needed for BZD binding suggests that there may be other regions in the ␣ subunit in addition to F64 that are involved in the formation of a GABA-binding site.
Chimeric uncoupling of BZD binding and potentiation. Despite high affinity BZD binding with ␣1␤2161 or ␣1␤2167, there are significant differences in the behavior of the resultant channels with regard to BZD allosteric coupling. By using two different assays (electrophysiological and equilibrium radioligand binding) and two different expression systems (X. laevis oocytes and HEK 293 cells), we have shown that the allosteric interactions between the GABA and BZD binding sites of ␣1␤2161 and ␣1␤2167 receptors are markedly decreased compared with wild-type ␣1␤2␥2S receptors (Figs. 4 and 6 ). Neither the decrease in diazepam potentiation of the GABA response nor the near abolishment in GABA potentiation of BZD binding is caused by a reduction in GABA sensitivity (Table 2) or muscimol binding affinity for ␣1␤2161 or ␣1␤2167 receptors. In addition, several pieces of evidence indicate that it is unlikely that the reduced potentiation is due to impaired assembly or expression of the 161 and 167 subunits: (1) B max for BZD binding of ␣1␤2161 and ␣1␤2167 receptors expressed in HEK 293 cells (Table 1) is similar to ␣1␤2␥2S receptors and suggests that these chimera-containing receptors are efficiently expressed, (2) ␣1␤2161 and ␣1␤2167 GABA EC 50 and K D values for muscimol binding are more similar to those of ␣1␤2␥2S than to those of ␣1␤2 receptors (Fig. 5, Table 2 ), suggesting full expression of a ␥2 element, and (3) ␤2161 and ␤2167 receptors expressed in X. laevis oocytes have maximal GABA-activated currents, similar to those of ␤2␥2S receptors.
Taken together, these results indicate that the decreased coupling of BZD binding and potentiation is an intrinsic property of the 161-and 167-containing receptors and demonstrate that transduction of high affinity BZD binding (binding indistinguishable from wild-type) to full agonist potentiation must require additional and/or different ␥2 subunit regions than those contained in the amino-terminal 167 amino acids of the ␥2S subunit. Furthermore, these results suggest that a ␥ element is responsible for the ability of GABA to potentiate BZD binding. Experiments are under way to delineate residues, downstream from 167, that are determinant for the allosteric interactions. In addition, these findings underscore the fact that a measured alteration in allosteric coupling does not necessarily imply any change in ligand binding.
Also of interest is the lack of measurable diazepam potentiation of the GABA response with any ␤2 subunit combination expressed in X. laevis oocytes. ␤2␥2S receptors display both GABA activation and BZD potentiation of the Cl Ϫ current (Table 2 ), yet ␤2161 and ␤2167 receptors seem to be devoid of diazepam response despite the fact that when they are coexpressed with ␣1, they exhibit BZD binding (Table 1) and diazepam potentiation (Fig. 4) . We postulate that the rightward shift in the GABA dose-response curve for ␤2␥2S receptors ( Fig. 5 ; Sigel et al., 1990 ) represents a diminished capacity for ␥2 GABA-binding regions to substitute for homologous ␣1 regions in the formation of a GABA-binding pocket at the interface with a ␤ subunit. Recent work indicates a similar inability of ␥2 to substitute for ␣1 in BZD actions (Amin et al., 1997) , even though ␤2␥2S receptors display BZD sensitivity akin to that of ␣1␤2␥2S receptors (Table 2 ; Sigel et al., 1990; Im et al., 1993) . If inefficient allosteric coupling in the chimeras is superimposed on an already low GABA binding affinity contributed by the ␥2 regions, this might make potentiation of the ␤2 receptors difficult to measure. Alternatively, residues carboxyl-terminal to ␥2L167 might be needed for formation of fully functional GABA or BZD binding pockets in ␤2 receptors. Finally, it is possible that our chimeras will not bind BZDs in the absence of an ␣ subunit. Whether ␤2 receptors have altered BZD binding or altered allosteric coupling of the GABA and BZD binding pockets requires further investigation.
Previous studies have shown that chronic exposure to GABA A receptor modulators, including BZDs, can cause a decrease in coupling between binding sites, as measured by potentiation of [ 3 H]flunitrazepam binding (Hu and Ticku, 1994; Friedman et al., 1996) . This observation has been postulated to represent one mechanism underlying drug tolerance. In ␣1␤2161 and ␣1␤2167 receptors, the GABA and BZD binding sites are already uncoupled; therefore, these chimeras can be used to glean structural information about regions of the ␥2S and ␣1 subunits involved in allosteric interactions. Mutation of these chimeric subunits such that coupling is enhanced will lead to a better understanding of allosteric cross-talk between binding sites and may help identify the structural elements underlying allosteric modulation. Studies using whole-cell and outside-out patch-clamp on chimeras expressed in HEK 293 cells also will be of inter-est, to determine the kinetics underlying these alterations in coupling. The chimeric subunits described in this report may be especially informative in this regard.
In summary, we demonstrated that ␥/␣ chimeras can be expressed and form functional GABA A receptors in the presence of wild-type subunits. We identified two domains of the ␥2 subunit, K41-W82 and R114-D161, that together are required for high affinity BZD binding. In these regions, several amino acid residues are not conserved between the ␣1 and ␥2 subunits and are likely candidates for BZD binding site residues. Notably, diazepam potentiation of the GABA response and GABA potentiation of BZD binding are reduced in chimeras containing these regions due to impaired allosteric coupling. Thus, by using intersubunit chimeras, the molecular dissection of multiple domains associated with ligand-binding sites has been described and distinguished from areas that function in allosteric coupling.
